Publications scientifiques sur les diagnostics non invasifs BioPredictive

Études évaluées par les pairs validant les diagnostics sanguins BioPredictive pour les maladies du foie — des cohortes pionnières aux méta-analyses à long terme.

5/436 Publications

Dyslipidemia Tout effacer
  1. Prognostic value of liver fibrosis and steatosis biomarkers in type-2 diabetes and dyslipidaemia.

    Perazzo H et al. · Aliment Pharmacol Ther · 2014

    FibroTest SteatoTest Metabolic

  2. Noninvasive biomarkers for the screening of fibrosis, steatosis and steatohepatitis in patients with metabolic risk factors: FibroTest-FibroMax experience. Key publication Review

    Munteanu M et al. · J Gastrointestin Liver Dis · 2008

    ActiTest AshTest FibroTest NashTest +6

  3. FibroMAX: towards a new universal biomarker of liver disease? Review

    Morra R et al. · Expert Rev Mol Diagn · 2007

    ActiTest AshTest FibroTest NashTest +7

  4. Screening for liver disease using non-invasive biomarkers (FibroTest, SteatoTest and NashTest) in patients with hyperlipidaemia.

    Ratziu V et al. · Aliment Pharmacol Ther · 2007

    FibroTest NashTest SteatoTest Metabolic

  5. Transient elastography: a new surrogate marker of liver fibrosis influenced by major changes of transaminases.

    Coco B et al. · J Viral Hepat · 2007

    FibroTest Alcohol HBV HCV +1

Affichage de la liste complète des résultats. La page est rendue côté serveur et non paginée.